Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can the run continue?? Yep!! Lets see this move higher!! JMO
Sarepta Therapeutics (SRPT)
28.73 ? -0.59 (-2.01%)
Volume: 1,829,407 @ 7:58:18 PM ET
Bid Ask Day's Range
28.87 29.2 28.15 - 29.37
SRPT Detailed Quote
reading, anny updates my friend ????? 'Sarepta Therapeutics (SRPT)'
earnings ????? patent ????? Sarepta Therapeutics (SRPT)'
Unreal? There isn't a good viable reason for this decrease,is there? Am I missing something?
Sarepta Therapeutics (SRPT)
29.63 ? -0.17 (-0.57%)
Volume: 706,483 @ 2:05:01 PM ET
Bid Ask Day's Range
29.62 29.66 29.17 - 29.999
SRPT Detailed Quote
Nice catch! Thanks for posting.
Just read this on Twitter, insurance companies caving IMO could explode
1st crack in the back... $ANTM Anthem has decided to OVERTURN its previous denial and will now cover Brody’s #Exondys51 $SRPT
Good precedent
SRPT News: Statement of Changes in Beneficial Ownership (4) 03/21/2017 06:08:55 PM
SRPT News: Statement of Changes in Beneficial Ownership (4) 03/21/2017 06:06:17 PM
SRPT News: Statement of Changes in Beneficial Ownership (4) 03/21/2017 06:03:10 PM
SRPT News: Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference 03/17/2017 08:30:00 AM
SRPT News: Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference 03/02/2017 06:00:00 PM
Sarepta Therapeutics (SRPT)
29.93 ? 0.25 (0.84%)
Volume: 856,246 @ 6:17:42 PM ET
Bid Ask Day's Range
29.55 30.55 29.54 - 30.17
SRPT Detailed Quote
The shorts seem to have ahold of the pps pretty much all the time? We just get moving higher and they sell it back down! Pretty much manipulation by those that can. JMO Sucks to be a shareholder that wants the pps to move higher.
Anybody know why this is fluctuating like a yo-yo?? Wow, so happy this morning now down almost a dollar since then
SRPT sells voucher for $125M, but is this a positive or negative going forward?
Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
Tuesday 02/21/2017 07:00 AM ET - BusinessWire via Dow Jones News
-- Sale of PRV Provides a Significant Infusion of Non-Dilutive Capital -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 21, 2017-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta received the PRV when EXONDYS 51(TM) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping.
SRPT News: Current Report Filing (8-k) 02/21/2017 07:28:41 AM
SRPT News: Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M 02/21/2017 07:00:00 AM
SRPT News: Sarepta Therapeutics to Announce Fourth Quarter & Full-Year 2016 Financial Results & Recent Corporate Developments on Februar... 02/15/2017 08:31:00 AM
SRPT News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 06:13:35 PM
SRPT News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 02:55:02 PM
Sarepta Therapeutics (SRPT)
29.32 ? 0.64 (2.23%)
Volume: 738,801 @ 11:14:57 AM ET
Bid Ask Day's Range
29.32 29.36 28.305 - 29.62
SRPT Detailed Quote
SRPT News: Current Report Filing (8-k) 02/21/2017 07:28:41 AM
SRPT News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01/31/2017 05:15:00 PM
SRPT News: Amended Statement of Ownership (sc 13g/a) 01/27/2017 06:02:19 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 01/24/2017 05:53:25 PM
SRPT News: Confidential Treatment Order (ct Order) 01/19/2017 01:01:12 PM
SRPT News: Amended Statement of Ownership (sc 13g/a) 01/10/2017 12:26:11 PM
Sarepta Therapeutics (SRPT)
27.83 ? -1.51 (-5.15%)
Volume: 2,045,834 @ 7:50:28 PM ET
Bid Ask Day's Range
27.75 29.22 27.83 - 29.44
SRPT Detailed Quote
ONLY TAKE $60M DOLLARS TO MOVE IT PENNIES
WHO WOULD WASTE THEIR TIME BUYING THIS?
NEWS OUT AND STILL ONLY UP PENNIES
At this point I'm enjoying the move back higher. Was able to pick up several calls when the pps was lower. Will be glad to buy my 40.00 put back when I see a little more green, big change from just a few days ago!! JMO
Sarepta Therapeutics Inc (NASDAQ:SRPT) Gets Off To A Running Start With Eteplirsen http://marketexclusive.com/sarepta-therapeutics-inc-nasdaqsrpt-gets-off-running-start-eteplirsen/68883/?icd1
Agreed that it is surprisingly quiet here. But I think that will change with the 10-K in February. Although based on their past few years, it might not be until late Feb or early Mar. Either way, that is the next official catalyst unless they have PRs or some M&A rumors.
How is this MB not filled with comments? YHOO MB is awful, there is no where else to go and yet this MB is near empty..... Lets work on that... GO SRPT Longs. Perhaps 1 more PR will keep this stock from drifting back below 30.
lot thought here, sprt
Looks like folks will need to cover! Glad I picked up a few calls when the pps was lower. Now just need to see where we go back to? JMO Good luck to all sfrx shareholders!!
Sarepta Therapeutics (SRPT)
27.43 ? -0.2 (-0.72%)
Volume: 1,565,895 @ 6:07:18 PM ET
Bid Ask Day's Range
27.01 27.41 26.66 - 27.79
SRPT Detailed Quote
SRPT News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/30/2016 05:05:00 PM
SRPT News: Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dyst... 12/19/2016 05:23:00 PM
SRPT News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/2016 06:00:00 PM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:29:06 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:27:29 AM
Love SRPT bought it $12. Investors I know this SRPT board you must check this out ARYC.003 click on twitter this looks like an srpt company
https://twitter.com/arrayit
Arrayit customers at Chemical Engineering Korea use Arrayit microarray platform to publish cholera detection advance
___________________________________________________________________
Arrayit reports microarray technology inquiry from next generation sequencing leader Direct Genomics Guangdong China
___________________________________________________________________
Arrayit selected for the 2016 Best of Sunnyvale Awards for a Biotechnology Company by Sunnyvale Business Recognition
___________________________________________________________________
Arrayit reports microarray technology sale to $233.2MM life sciences leader Fluidigm Nasdaq:FLDM Markham ON Canada
___________________________________________________________________
Arrayit reports microarray tech inquiry from $56.7B pharmaceutical giant Abbott Laboratories NYSE:ABT Carlsbad CA
___________________________________________________________________
Arrayit reports microarray technology sale to $56.6B life sciences juggernaut Thermo Fisher NYSE:TMO Pittsburgh PA
___________________________________________________________________
Arrayit reports microarray technology inquiry from top RNA hybridization leaders Advanced Cell Diagnostics Newark CA
___________________________________________________________________
Arrayit reports microarray reagents sale to advanced molecular diagnostics distributor AH Diagnostics Aarhus
___________________________________________________________________
Arrayit reports microarray technology sale to top EU life sciences distributor Novusci Bedfordshire United Kingdom
___________________________________________________________________
Arrayit quotes $7.1 million variation identification platform (VIP) genotyping package to top clinical testing laboratory in Southeast Asia
___________________________________________________________________
Arrayit reports $393,294 sales and marketing lead from a top wellness and clinical testing company in European Union
___________________________________________________________________
Arrayit reports $7,500 microarray technology sale to top research scientists Oklahoma State University Stillwater OK
___________________________________________________________________
Arrayit's microarray manufacturing technology enables these new molecular diagnostic devices
do ur dd
Sarepta Therapeutics (SRPT)
34.82 ? 0.72 (2.11%)
Volume: 1,557,214 @ 7:59:42 PM ET
Bid Ask Day's Range
34.65 34.82 33.71 - 35.03
SRPT Detailed Quote
SRPT News: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/2016 06:00:00 PM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:29:06 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:27:29 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:21:12 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 11/10/2016 08:20:03 AM
In at $40.35. Is this just election jitters?
TS
Sarepta Therapeutics (SRPT)
40.9 ? 0.09 (0.22%)
Volume: 2,741,437 @ 7:59:47 PM ET
Bid Ask Day's Range
40.75 42.33 39.56 - 42.51
SRPT Detailed Quote
SRPT News: Statement of Ownership (sc 13g) 10/28/2016 09:19:59 AM
SRPT News: Current Report Filing (8-k) 10/27/2016 07:28:36 AM
SRPT News: Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments 10/27/2016 07:00:00 AM
SRPT News: Statement of Changes in Beneficial Ownership (4) 10/24/2016 04:36:37 PM
SRPT News: Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016 10/24/2016 08:30:00 AM
Sarepta Therapeutics (SRPT)
40.9 ? 0.09 (0.22%)
Volume: 2,741,437 @ 7:59:47 PM ET
Bid Ask Day's Range
40.75 42.33 39.56 - 42.51
SRPT Detailed Quote
About to test 50. Below that will likely hit a lot of stops IMO. Timberrrrr
SRPT News: CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sarepta’s Patient Support Program for Duc... 10/06/2016 12:08:00 PM
SRPT News: Confidential Treatment Order (ct Order) 10/04/2016 03:57:59 PM
SRPT News: Current Report Filing (8-k) 10/04/2016 07:07:28 AM
SRPT News: Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Ut... 10/04/2016 07:00:00 AM
SRPT News: Current Report Filing (8-k) 09/30/2016 04:16:23 PM
Sarepta Therapeutics (SRPT)
54.08 ? -0.11 (-0.20%)
Volume: 267,623 @ 10:06:47 AM ET
Bid Ask Day's Range
54.07 54.27 53.77 - 55.02
SRPT Detailed Quote
Well, new analyst report is saying there looking at a higher pps? I'm taking it with a grain of salt and Who knows some days where the pps might be? JMO
Why would it go higher? Seems like a lack of reimbursement is letting the air out of this ballon IMO.
At the speed we went higher it scares me as to what speed we could go back down. Only my opinion and who knows maybe we go higher? I'm sitting out for now. Just keeping a few shares in play.
It's likely to happen. If so then I'd expect it to hit the single digits in a hurry. All IMO.
The reason I cut back my exposure, what happens if more insurance companies say they won't cover the drug? JMO nothing more.
Looks like it's ready to begin imploding. Too much risk at this level considering lack of confidence in the data and no insurance coverage.
I picked up a buy to open put @ 50.00 just to cma after selling half my shares also in the 60's. To nervous with the election, interest rate scares, the craziness that seems to be around. JMO Good luck to all shareholders!!
i was long and did the same.... insurance politics could bring this down into the the 30's... i will add at that point.
Ouch, sold at $59. I'm done with this one for now.
Selling everything at 65
CATB making an early AM run (JV w/ SRPT could be big for them)
Followers
|
128
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3058
|
Created
|
11/16/05
|
Type
|
Free
|
Moderators |
http://www.sareptatherapeutics.com/
http://www.antivirals.com/
http://finance.yahoo.com/q/h?s=AVII
http://www.form4oracle.com/company?cik=0000873303&ticker=avii
http://www.secform4.com/insider-trading/873303.htm
Sarepta Therapeutics - formerly AVI BioPharma - remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta's unique technology has yielded a diverse pipeline of RNA-based therapeutics that include our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world's most lethal infectious diseases.
Our exceptional science- and commercialization-focused team is committed to realizing our vision of becoming a leading, independent biotechnology company dedicated to translating our RNA-based science into transformational therapeutics and, most importantly, bringing these novel therapeutics to patients who have no other options.
AVI BioPharma, Inc., a biopharmaceutical company, develops therapeutic products principally based on NEUGENE antisense technology. It offers various drugs for the treatment of cardiovascular diseases, infectious diseases, cancer, and polycystic kidney diseases, as well as for regulating drug metabolism. The company has collaboration agreement with Chiron Corporation for research, development, and commercialization of antisense therapeutics against hepatitis C virus; Cook Group Incorporated for the development and commercialization of products for vascular diseases; and Ercole Biotech, Inc. to identify and develop drugs that direct the splicing of messenger RNA to treat a range of genetic and acquired diseases. AVI BioPharma was founded in 1980 and is based in Portland, Oregon.
Form Type | Received | Period Ending | Size | Report |
---|---|---|---|---|
PRE 14A | May 16, 2016 | Jun 27, 2016 | 2.7 MB | PDF RTF HTML XLS |
SC 13G | May 6, 2016 | 14.4 KB | PDF RTF HTML XLS | |
8-K | May 5, 2016 | May 5, 2016 | 72.4 KB | PDF RTF HTML XLS |
10-Q | May 5, 2016 | Mar 31, 2016 | 5.0 MB | PDF RTF HTML XLS |
10-K/A | Apr 29, 2016 | Dec 31, 2015 | 2.0 MB | PDF RTF HTML XLS |
4 | Apr 22, 2016 | Apr 20, 2016 | 5.0 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 7.4 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 5.2 KB | PDF RTF HTML XLS |
4 | Mar 17, 2016 | Mar 14, 2016 | 4.7 KB | PDF RTF HTML XLS |
8-K | Mar 8, 2016 | Mar 7, 2016 | 30.8 KB | PDF RTF HTML XLS |
Phone and email address..................Lead investigator in the DMD trial.....London College of Medicine
http://www1.imperial.ac.uk/medicine/people/f.muntoni/
DISCLAIMER:
•The Board Monitor and The Board Assistants herewith, Are not licensed brokers and assume NO Responsibility for the Actions,
Investment decisions, and or Messages Posted on this Forum.
•We do NOT recommend that Anyone Buy or Sell any Securities Posted Herewith.
Any Trade entered into Risks the Possibility of Losing the Funds Invested.
•There are NO Guarantees when Buying or Selling Any Security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |